ZX008 (Fenfluramine Hydrochloride) + Matching Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Dravet Syndrome
Conditions
Dravet Syndrome, Seizure Disorder
Trial Timeline
Jan 15, 2016 → Jul 29, 2020
NCT ID
NCT02682927About ZX008 (Fenfluramine Hydrochloride) + Matching Placebo
ZX008 (Fenfluramine Hydrochloride) + Matching Placebo is a phase 3 stage product being developed by UCB for Dravet Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT02682927. Target conditions include Dravet Syndrome, Seizure Disorder.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02926898 | Phase 3 | Completed |
| NCT02682927 | Phase 3 | Completed |
Competing Products
15 competing products in Dravet Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ZX008 (Fenfluramine Hydrochloride) | UCB | Phase 3 | 74 |
| ZX008 (Fenfluramine Hydrochloride) | UCB | Phase 3 | 74 |
| ZX008 0.2 to 0.8 mg/kg/day + Cannabidiol | UCB | Phase 1 | 30 |
| fenfluramine | UCB | Approved | 82 |
| Fenfluramine Hydrochloride | UCB | Pre-clinical | 20 |
| ZX008 (Fenfluramine Hydrochloride) + Matching Placebo | UCB | Phase 3 | 74 |
| ZX008 (Fenfluramine Hydrochloride) | UCB | Phase 3 | 74 |
| fenfluramine | UCB | Phase 3 | 74 |
| Clobazam | Lundbeck | Phase 3 | 74 |
| Clobazam + Placebo | Lundbeck | Phase 3 | 74 |
| Epidiolex 100 mg/mL Oral Solution | Jazz Pharmaceuticals | Approved | 82 |
| zorevunersen | Stoke Therapeutics | Phase 3 | 72 |
| STK-001 - Single Ascending Doses + STK-001 - Multiple Ascending Doses | Stoke Therapeutics | Phase 1/2 | 36 |
| zorevunersen (STK-001) | Stoke Therapeutics | Phase 2 | 47 |
| Clemizole HCl + Placebo | Harmony Biosciences | Phase 3 | 72 |